News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
GlaxoSmithKline Buys UCB Group Emerging Market Activities for $667.2 Million
January 23, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BRUSSELS, Jan 23 (Reuters) - GlaxoSmithKline Plc has agreed to buy Belgian pharmaceutical group UCB's operations and commercial rights in a number of emerging markets for 515 million euros.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
GlaxoSmithKline
MORE ON THIS TOPIC
MASH
Madrigal Dives Further Into MASH With up to $4.4B siRNA Deal With Chinese Biotech
February 11, 2026
·
2 min read
·
Tristan Manalac
Artificial intelligence
AI Is Changing Pharma’s Bottom Line Now—But Not Through Splashy Drug Discovery
February 11, 2026
·
8 min read
·
Annalee Armstrong
Mergers & acquisitions
Eli Lilly Enters CAR T Realm With $2.4B Orna Buy, Starting With Autoimmune
February 9, 2026
·
2 min read
·
Dan Samorodnitsky
Insights
Programmable RNA 2.0: Beyond the First mRNA Revolution
February 5, 2026
·
1 min read
·
Jennifer Smith-Parker
